Emerging studies suggest Retatrutide , a dual stimulator targeting both incretin and glucose-dependent insulinotropic polypeptide , appears to offer a significant development for obesity management . Early patient tests have demonstrated substantial losses in abdominal tissue, conceivably outperforming other body composition treatments. Nevertheles